NVP

EQT Private Equity to Acquire Avetta from WCAS

Retrieved on: 
Tuesday, April 2, 2024
Automation, Health, Software as a service, Citigroup, Growth, Goldman Sachs, Partnership, Risk, NVP, ESG, TCV, Ropes & Gray, General partnership, AI, Accident, Investment, Kirkland & Ellis, EQT, Safety, SCRM, WCAS, Asset management

Avetta's solution improves the resilience of supply chains worldwide by helping hiring clients and suppliers manage their supply chain risk effectively and improve safety, security, sustainability, worker competency, and performance across major industries

Key Points: 
  • Avetta's solution improves the resilience of supply chains worldwide by helping hiring clients and suppliers manage their supply chain risk effectively and improve safety, security, sustainability, worker competency, and performance across major industries
    NEW YORK, April 2, 2024 /PRNewswire/ -- EQT Private Equity announced today that the EQT X fund ("EQT") has agreed to acquire Avetta (the "Company") from Welsh, Carson, Anderson & Stowe ("WCAS").
  • Together, EQT and Avetta are committed to investing in innovation to address the critical challenges facing global supply chains today.
  • Arvindh Kumar, Partner and Co-Head of Technology within EQT's Private Equity Advisory Team, said, "Avetta's leadership position, world-class SaaS platform, and commitment to ESG represent a highly thematic investment opportunity for EQT.
  • Avetta is an excellent example of how WCAS supports accelerating value creation and driving technology businesses to the next level.

EQT Private Equity to Acquire Avetta from WCAS

Retrieved on: 
Tuesday, April 2, 2024
Automation, Health, Software as a service, Citigroup, Growth, Goldman Sachs, Partnership, Risk, NVP, ESG, TCV, Ropes & Gray, General partnership, AI, Accident, Investment, Kirkland & Ellis, EQT, Safety, SCRM, WCAS, Asset management

Avetta's solution improves the resilience of supply chains worldwide by helping hiring clients and suppliers manage their supply chain risk effectively and improve safety, security, sustainability, worker competency, and performance across major industries

Key Points: 
  • Avetta's solution improves the resilience of supply chains worldwide by helping hiring clients and suppliers manage their supply chain risk effectively and improve safety, security, sustainability, worker competency, and performance across major industries
    NEW YORK, April 2, 2024 /PRNewswire/ -- EQT Private Equity announced today that the EQT X fund ("EQT") has agreed to acquire Avetta (the "Company") from Welsh, Carson, Anderson & Stowe ("WCAS").
  • Together, EQT and Avetta are committed to investing in innovation to address the critical challenges facing global supply chains today.
  • Arvindh Kumar, Partner and Co-Head of Technology within EQT's Private Equity Advisory Team, said, "Avetta's leadership position, world-class SaaS platform, and commitment to ESG represent a highly thematic investment opportunity for EQT.
  • Avetta is an excellent example of how WCAS supports accelerating value creation and driving technology businesses to the next level.

ProPricer Launches Cash Flow Pro: A Game-Changer in Financial Reporting for Government Contractors

Retrieved on: 
Thursday, August 24, 2023
Government, NVP, Internal rate of return, Depreciation, Financial management, IRR, Commercial property, Risk management, Microsoft Excel

Seamlessly integrating with ProPricer's acclaimed Contractor Edition platform, Cash Flow Pro empowers contractors to wield comprehensive cash flow insights, streamline reporting processes, and elevate compliance measures.

Key Points: 
  • Seamlessly integrating with ProPricer's acclaimed Contractor Edition platform, Cash Flow Pro empowers contractors to wield comprehensive cash flow insights, streamline reporting processes, and elevate compliance measures.
  • Nik Slepushkin, Product Director at ProPricer, highlighted the game-changing potential of Cash Flow Pro, stating, "Cash Flow Pro reshapes the way government contractors approach financial reporting.
  • Key Features That Set Cash Flow Pro Apart:
    Holistic Cash Flow Analysis: Cash Flow Pro provides an accurate evaluation of cash flow implications by factoring in diverse elements such as milestones, billing methods, payment delays, withholdings, and depreciation.
  • Compliance and Transparency: Cash Flow Pro ensures adherence to financial regulations through systematic and auditable cash flow reporting.

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

Retrieved on: 
Monday, August 21, 2023
Maintenance, Esophagitis, Symantec Endpoint Protection, NVP, NDA, Gastroesophageal reflux disease, Tablet, GERD, Vonoprazan, PDUFA, CRL, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Dietary supplement, Pharmaceutical industry

The additional stability was required for the FDA to complete its NDA review for vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis.

Key Points: 
  • The additional stability was required for the FDA to complete its NDA review for vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis.
  • Phathom resubmitted the NDA for vonoprazan for Erosive GERD in May 2023 on the basis of three months of stability data and was assigned a PDUFA goal date of November 17, 2023.
  • “The latest stability data confirm that our minor product reformulation has limited the presence of NVP, and we believe these data comfortably support the proposed shelf life for vonoprazan tablets.
  • If approved, a combined U.S. commercial launch for Erosive GERD and H. pylori is planned for the fourth quarter of 2023.

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

Retrieved on: 
Tuesday, May 23, 2023
Maintenance, Esophagitis, Symantec Endpoint Protection, NVP, New Drug Application, NDA, Lansoprazole, Gastroesophageal reflux disease, Tablet, GERD, Patient, Vonoprazan, Erosion, Growth, CRL, PPI, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Agency

This resubmission responds to the Complete Response Letter (CRL) issued by the FDA in February 2023 relating to specifications and controls for a nitrosamine drug substance related impurity, N-nitroso-vonoprazan (NVP).

Key Points: 
  • This resubmission responds to the Complete Response Letter (CRL) issued by the FDA in February 2023 relating to specifications and controls for a nitrosamine drug substance related impurity, N-nitroso-vonoprazan (NVP).
  • As previously communicated, Phathom implemented mitigation measures, including a minor drug product tablet reformulation, to inhibit the growth of NVP, and has been conducting a stability program to demonstrate these measures are effective and support the commercial shelf life.
  • As agreed with the Agency, we plan to provide the final six-month stability data during their review as it becomes available.
  • If the NDA is approved, a combined U.S. commercial launch for the Erosive GERD and H. pylori indications is planned for the fourth quarter of 2023.

Volition raises $11M to scale the world's largest industrial parts marketplace

Retrieved on: 
Thursday, May 25, 2023
Fortune 500, B2B, Catalog, NVP, Newark Venture Partners, Sale, Amazon, William J. Nicks Building, Collection, SAN, Commerce, Engineering, Jewellery, Ali Baba, Automation, Cryptocurrency, Online shopping, Video game, Volition

Volition is the first and only online industrial parts marketplace designed specifically for the needs of the hardware development world.

Key Points: 
  • Volition is the first and only online industrial parts marketplace designed specifically for the needs of the hardware development world.
  • "Volition is the first marketplace for the $2T industrial components industry that helps engineering and purchasing teams find and buy all of the parts they need to prototype and manufacture their designs," said Nick Pinkston, co-founder and CEO of Volition.
  • This new funding allows them to further scale their marketplace, as well as build out new features that let customers improve their sourcing while increasing retention dramatically.
  • He created HackPittsburgh (the first makerspace in Pittsburgh) and CloudFab (custom manufacturing marketplace) before starting Plethora.

Phathom Pharmaceuticals Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, May 10, 2023
Helicobacter pylori, Esophagitis, Failure, DUAL, NVP, Clinical trial, NDA, Enzyme inhibitor, N, PPI, Chemistry, GERD, Phase 10, Patient, Erosion, Research, FDA, Pharmaceutical industry, Bank

FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided updates on recent regulatory progress.

Key Points: 
  • FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided updates on recent regulatory progress.
  • In January 2023, Phathom shared positive topline results from the Phase 3 PHALCON-NERD-301 trial evaluating the daily dosing of vonoprazan for Non-Erosive GERD.
  • First Quarter 2023 Financial Results:
    Net loss for the first quarter ended March 31, 2023 was $37.8 million, compared to $40.7 million for first quarter 2022.
  • First quarter 2023 net loss included a non-cash charge related to stock-based compensation of $7.0 million compared to $5.8 million for first quarter 2022.

Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch

Retrieved on: 
Tuesday, April 4, 2023
Helicobacter pylori, Esophagitis, NVP, PAS, NDA, GERD, Patient, Growth, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical device, Agency

Both CRLs were solely related to specifications and controls for a nitrosamine drug substance related impurity, N-nitroso-vonoprazan (NVP).

Key Points: 
  • Both CRLs were solely related to specifications and controls for a nitrosamine drug substance related impurity, N-nitroso-vonoprazan (NVP).
  • Phathom has shared available stability data with the FDA on this reformulation and received feedback on the resubmission requirements, including the expected stability data requirements.
  • Based on this input, Phathom anticipates resubmitting the NDA for erosive esophagitis in the second quarter of 2023 which, if approved, could lead to a combined commercial launch of the erosive esophagitis and H. pylori indications in the fourth quarter of 2023.
  • Phathom also anticipates submitting a PAS for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® with FDA action expected in the fourth quarter of 2023.

Bow River Capital Hires Veteran Software Executive and Investor Matt Warta as Managing Director on Its Software Growth Equity Team

Retrieved on: 
Friday, March 31, 2023
Software as a service, Norwest Venture Partners, NVP, General partnership, Software, LP record, Andrew Kerr (festival co-founder), Fortune 500, Ernst & Young Entrepreneur of the Year Award, SGE, Dysbiosis, Cryptocurrency

DENVER, March 31, 2023 /PRNewswire/ -- Bow River Capital, a Denver-based alternative asset manager, announced today that Matt Warta, an experienced Software-as-a-Service (SaaS) executive and operator with more than 20 years of experience, has joined the firm as a Managing Director on the Software Growth Equity (SGE) team.

Key Points: 
  • DENVER, March 31, 2023 /PRNewswire/ -- Bow River Capital, a Denver-based alternative asset manager, announced today that Matt Warta, an experienced Software-as-a-Service (SaaS) executive and operator with more than 20 years of experience, has joined the firm as a Managing Director on the Software Growth Equity (SGE) team.
  • Warta will oversee the sourcing and due diligence of majority-control transactions, will lead our board of directors across multiple SaaS platform companies, and build deep relationships with founders and tech CEOs in Bow River Capital's Software Growth Equity portfolio.
  • On March 15, 2023, the Bow River Capital Software Growth Equity team successfully closed Bow River Capital Software Growth Equity Fund II (SGE Fund II).
  • SGE Fund II was significantly oversubscribed and closed above its $500M target with $605M of committed capital from a broad group of investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT

Retrieved on: 
Wednesday, March 1, 2023
FDA, Pomerantz, LLP, NDA, Vonoprazan, PDUFA, NVP, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT).

Key Points: 
  • NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Phathom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.